GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » ROA %

Talis Biomedical (Talis Biomedical) ROA % : -53.33% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Talis Biomedical's annualized Net Income for the quarter that ended in Dec. 2023 was $-53.84 Mil. Talis Biomedical's average Total Assets over the quarter that ended in Dec. 2023 was $100.95 Mil. Therefore, Talis Biomedical's annualized ROA % for the quarter that ended in Dec. 2023 was -53.33%.

The historical rank and industry rank for Talis Biomedical's ROA % or its related term are showing as below:

TLIS' s ROA % Range Over the Past 10 Years
Min: -187.53   Med: -82.03   Max: -46.98
Current: -49.42

During the past 6 years, Talis Biomedical's highest ROA % was -46.98%. The lowest was -187.53%. And the median was -82.03%.

TLIS's ROA % is ranked worse than
80.95% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: -1.84 vs TLIS: -49.42

Talis Biomedical ROA % Historical Data

The historical data trend for Talis Biomedical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical ROA % Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -148.06 -81.32 -82.73 -51.95 -46.98

Talis Biomedical Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.28 -47.18 -46.96 -54.47 -53.33

Competitive Comparison of Talis Biomedical's ROA %

For the Medical Devices subindustry, Talis Biomedical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's ROA % distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's ROA % falls into.



Talis Biomedical ROA % Calculation

Talis Biomedical's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-62.007/( (169.29+94.674)/ 2 )
=-62.007/131.982
=-46.98 %

Talis Biomedical's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-53.84/( (107.228+94.674)/ 2 )
=-53.84/100.951
=-53.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Talis Biomedical  (NAS:TLIS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-53.84/100.951
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-53.84 / 0.604)*(0.604 / 100.951)
=Net Margin %*Asset Turnover
=-8913.91 %*0.006
=-53.33 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Talis Biomedical ROA % Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical (Talis Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3400 Bridge Parkway, Redwood City, CA, USA, 94065
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063

Talis Biomedical (Talis Biomedical) Headlines

From GuruFocus

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-20-2022

Talis Biomedical Reports Third Quarter 2022 Financial Results

By Value_Insider Value_Insider 11-03-2022

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-30-2022